Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 15;11(7):1274.
doi: 10.3390/diagnostics11071274.

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study

Manon Degez  1 , Hélène Caillon  2 , Anne Chauviré-Drouard  3 , Maxime Leroy  4 , David Lair  5 , Norbert Winer  1   3 , Thibault Thubert  1   3 , Pauline Le Floch  6 , Valérie Desroys du Roure  7 , Mélanie Randet  8 , Guillaume Ducarme  9 , Vincent Dochez  1   3
Affiliations

HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study

Manon Degez et al. Diagnostics (Basel). .

Abstract

Background: Endometrial cancer is the most common pelvic gynecological cancer in France. The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies. The treatment is very codified and consists of a surgical intervention for anatomopathological analysis. The latter is frequently reassuring. These interventions are often performed in mild situations and there is currently no element to be sufficiently reassuring to avoid surgery. This study aims to explore the sensitivity of an innovative marker: Human Epididymis 4 (HE4) in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.

Methods: This is a prospective multicenter diagnostic study with three centers involved. Inclusion criteria are any patient with post-menopausal bleeding who is to undergo hysteroscopy, endometrial biopsy, or endometrial resection. In accordance with the recommendations for the management of post-menopausal bleedings, the medical conduct consists of performing a clinical examination, an ultrasound and, in general, even in case of paraclinical examination reassuring, an anatomopathological analysis. This pathological analysis can be obtained in several ways: biopsy, hysteroscopy-curettage (which is the most frequently performed surgery), and hysterectomy. Our protocol consists of taking a blood sample from each woman who will undergo one of the interventions mentioned above. The dosage of HE4 and CA125 requires the withdrawal of an additional heparinized tube during the preoperative assessment usually performed. This research is therefore classified as non-interventional. The primary outcome is to evaluate the sensitivity of the HE4 marker in patients with postmenopausal bleeding in the diagnosis of endometrial cancer. The secondary outcomes are other parameters (specificity, VPP, VPN) of HE4, Evaluating the diagnostic capabilities of the CA125 marker alone and associated with HE4, as well as those of the REM and REM-B algorithms. We aim to include 100 patients over a period of one year in three centers.

Discussion: As of now, there is no biological marker used in routine practice in the diagnosis of endometrial cancer. The ultimate goal of HE4 in endometrial cancer is to avoid surgery for those who are identified as non-sick. This study is the precursor of others for use in routine practice, HE4 would represent a great help to diagnosis if our study demonstrates it as reliable in the management of these patients and avoid many unnecessary and risky surgeries.

Keywords: CA125; HE4; endometrial cancer; human epididymis protein 4; hysteroscopy; postmenopausal bleeding.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Jamison P.M., Noone A.-M., Ries L.A.G., Lee N.C., Edwards B.K. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol. Biomark. Prev. 2013;22:233–241. doi: 10.1158/1055-9965.EPI-12-0996. - DOI - PubMed
    1. Weiderpass E., Antoine J., Bray F.I., Oh J.-K., Arbyn M. Trends in corpus uteri cancer mortality in member states of the European Union. Eur. J. Cancer. 2014;50:1675–1684. doi: 10.1016/j.ejca.2014.02.020. - DOI - PubMed
    1. Defossez G., Le Guyader-Peyrou S., Uhry Z., Grosclaude P., Colonna M., Dantony E., Delafosse P., Molinié F., Woronoff A.S., Bouvier A.M., et al. Estimations Nationales de l’incidence et de la Mortalité par Cancer en France Métropolitaine Entre 1990 et 2018. Santé publique; Saint-Maurice, France: 2019. [(accessed on 9 June 2020)]. Volume 1–Tumeurs solides.372p. Available online: http://www.santepubliquefrance.fr/
    1. Institut National Du Cancer Cancer De L’endomètre: Synthèse Des Recommandations. [Internet] [(accessed on 19 May 2020)]; Available online: https://www.e-cancer.fr.